221 related articles for article (PubMed ID: 34988022)
1. Interest and Limits of [
Jouberton E; Schmitt S; Maisonial-Besset A; Chautard E; Penault-Llorca F; Cachin F
Front Oncol; 2021; 11():789769. PubMed ID: 34988022
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. Apoptotic PET Imaging of Rat Pulmonary Fibrosis with Small-Molecule Radiotracer.
Xiong Y; Nie D; Liu S; Ma H; Su S; Sun A; Zhao J; Zhang Z; Xiang X; Tang G
Mol Imaging Biol; 2019 Jun; 21(3):491-499. PubMed ID: 30167994
[TBL] [Abstract][Full Text] [Related]
4. Radiopharmacological evaluation of 6-deoxy-6-[18F]fluoro-D-fructose as a radiotracer for PET imaging of GLUT5 in breast cancer.
Wuest M; Trayner BJ; Grant TN; Jans HS; Mercer JR; Murray D; West FG; McEwan AJ; Wuest F; Cheeseman CI
Nucl Med Biol; 2011 May; 38(4):461-75. PubMed ID: 21531283
[TBL] [Abstract][Full Text] [Related]
5. Ferret thoracic anatomy by 2-deoxy-2-(18F)fluoro-D-glucose (18F-FDG) positron emission tomography/computed tomography (18F-FDG PET/CT) imaging.
Wu A; Zheng H; Kraenzle J; Biller A; Vanover CD; Proctor M; Sherwood L; Steffen M; Ng C; Mollura DJ; Jonsson CB
ILAR J; 2012; 53(1):E9-21. PubMed ID: 23382267
[TBL] [Abstract][Full Text] [Related]
6. [
Jouberton E; Schmitt S; Chautard E; Maisonial-Besset A; Roy M; Radosevic-Robin N; Chezal JM; Miot-Noirault E; Bouvet Y; Cachin F
EJNMMI Res; 2020 Jan; 10(1):2. PubMed ID: 31907640
[TBL] [Abstract][Full Text] [Related]
7. Predictive Value of [
Gu B; Liu S; Sun Y; Zhang J; Zhang Y; Xu X; Yuan H; Wang M; Zhang Y; Yang Z
Mol Imaging Biol; 2019 Jun; 21(3):538-548. PubMed ID: 30218389
[TBL] [Abstract][Full Text] [Related]
8. Molecular Imaging of GLUT1 and GLUT5 in Breast Cancer: A Multitracer Positron Emission Tomography Imaging Study in Mice.
Wuest M; Hamann I; Bouvet V; Glubrecht D; Marshall A; Trayner B; Soueidan OM; Krys D; Wagner M; Cheeseman C; West F; Wuest F
Mol Pharmacol; 2018 Feb; 93(2):79-89. PubMed ID: 29142019
[TBL] [Abstract][Full Text] [Related]
9. [
Hovhannisyan N; Fillesoye F; Guillouet S; Ibazizene M; Toutain J; Gourand F; Valable S; Plancoulaine B; Barré L
Theranostics; 2018; 8(16):4563-4573. PubMed ID: 30214639
[TBL] [Abstract][Full Text] [Related]
10. Dynamic 2-Deoxy-2-[
Kristian A; Holtedahl JE; Torheim T; Futsaether C; Hernes E; Engebraaten O; Mælandsmo GM; Malinen E
Mol Imaging Biol; 2017 Apr; 19(2):271-279. PubMed ID: 27541026
[TBL] [Abstract][Full Text] [Related]
11.
Parihar AS; Mittal BR; Kumar R; Shukla J; Bhattacharya A
Thyroid; 2020 Apr; 30(4):557-567. PubMed ID: 31870227
[No Abstract] [Full Text] [Related]
12.
Elvas F; Boddaert J; Vangestel C; Pak K; Gray B; Kumar-Singh S; Staelens S; Stroobants S; Wyffels L
J Nucl Med; 2017 Apr; 58(4):665-670. PubMed ID: 27879368
[TBL] [Abstract][Full Text] [Related]
13. Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2'-deoxy-2'-[18F] fluoro-D-glucose-PET/CT scans to predict survival early during treatment of locally advanced non-small cell lung cancer (NSCLC).
Fledelius J; Khalil AA; Hjorthaug K; Frøkiaer J
J Med Imaging Radiat Oncol; 2016 Apr; 60(2):231-8. PubMed ID: 26678718
[TBL] [Abstract][Full Text] [Related]
14. An evaluation of 2-deoxy-2-[18F]fluoro-D-glucose and 3'-deoxy-3'-[18F]-fluorothymidine uptake in human tumor xenograft models.
Keen H; Pichler B; Kukuk D; Duchamp O; Raguin O; Shannon A; Whalley N; Jacobs V; Bales J; Gingles N; Ricketts SA; Wedge SR
Mol Imaging Biol; 2012 Jun; 14(3):355-65. PubMed ID: 21761255
[TBL] [Abstract][Full Text] [Related]
15. Positron emission tomography/computed tomography using 2-deoxy-2-fluoro-18-fluoro-D-glucose peri-tumoral halo uptake layer method outperforms magnetic resonance imaging and ultrasound methods in tumor size measurement of breast cancer.
Wu Y; Lu Y; Xu C; Lin B
Oncol Lett; 2020 Jun; 19(6):3881-3888. PubMed ID: 32391098
[TBL] [Abstract][Full Text] [Related]
16. Is (18)F-FDG PET really a promising marker for clinically relevant atherosclerosis?
Brammen L; Palumbo B; Lupattelli G; Sinzinger H
Hell J Nucl Med; 2014; 17(1):62-3. PubMed ID: 24701595
[TBL] [Abstract][Full Text] [Related]
17. Comparisons between glucose analogue 2-deoxy-2-((18)F)fluoro-D-glucose and (18)F-sodium fluoride positron emission tomography/computed tomography in breast cancer patients with bone lesions.
Capitanio S; Bongioanni F; Piccardo A; Campus C; Gonella R; Tixi L; Naseri M; Pennone M; Altrinetti V; Buschiazzo A; Bossert I; Fiz F; Bruno A; DeCensi A; Sambuceti G; Morbelli S
World J Radiol; 2016 Feb; 8(2):200-9. PubMed ID: 26981229
[TBL] [Abstract][Full Text] [Related]
18. New PET radiopharmaceuticals beyond FDG for brain tumor imaging.
Gulyás B; Halldin C
Q J Nucl Med Mol Imaging; 2012 Apr; 56(2):173-90. PubMed ID: 22617239
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of [
Jiang H; Zhang R; Jiang H; Zhang M; Guo W; Feng G; Pan W; Xu H; Wang S
Nucl Med Biol; 2019; 72-73():36-44. PubMed ID: 31330410
[TBL] [Abstract][Full Text] [Related]
20. 3'-deoxy-3'-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography.
Barthel H; Cleij MC; Collingridge DR; Hutchinson OC; Osman S; He Q; Luthra SK; Brady F; Price PM; Aboagye EO
Cancer Res; 2003 Jul; 63(13):3791-8. PubMed ID: 12839975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
